Development  ||| S:0 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
Fibromyalgia  ||| S:19 E:32 ||| NNP
Burden  ||| S:32 E:39 ||| NNP
Assessment ||| S:39 E:49 ||| NNP
:  ||| S:49 E:51 ||| :
measuring  ||| S:51 E:61 ||| VBG
the  ||| S:61 E:65 ||| DT
multifaceted  ||| S:65 E:78 ||| JJ
burden  ||| S:78 E:85 ||| NN
of  ||| S:85 E:88 ||| IN
fibromyalgia  ||| S:88 E:101 ||| VBG
To  ||| S:101 E:104 ||| TO
develop  ||| S:104 E:112 ||| VB
a  ||| S:112 E:114 ||| DT
questionnaire  ||| S:114 E:128 ||| NN
assessing  ||| S:128 E:138 ||| VBG
the  ||| S:138 E:142 ||| DT
burden  ||| S:142 E:149 ||| NN
of  ||| S:149 E:152 ||| IN
fibromyalgia ||| S:152 E:164 ||| NN
's  ||| S:164 E:167 ||| POS
impacts  ||| S:167 E:175 ||| NN
on  ||| S:175 E:178 ||| IN
patients ||| S:178 E:186 ||| NNS
'  ||| S:186 E:188 ||| POS
lives ||| S:188 E:193 ||| NNS
.  ||| S:193 E:195 ||| .
A  ||| S:195 E:197 ||| DT
literature  ||| S:197 E:208 ||| NN
review  ||| S:208 E:215 ||| NN
was  ||| S:215 E:219 ||| VBD
conducted  ||| S:219 E:229 ||| VBN
to  ||| S:229 E:232 ||| TO
identify  ||| S:232 E:241 ||| VB
impacts  ||| S:241 E:249 ||| VBN
of  ||| S:249 E:252 ||| IN
fibromyalgia  ||| S:252 E:265 ||| NN
and  ||| S:265 E:269 ||| CC
their  ||| S:269 E:275 ||| PRP$
consequences  ||| S:275 E:288 ||| NNS
on  ||| S:288 E:291 ||| IN
patients ||| S:291 E:299 ||| NNS
'  ||| S:299 E:301 ||| POS
lives ||| S:301 E:306 ||| NNS
.  ||| S:306 E:308 ||| .
Exploratory  ||| S:308 E:320 ||| JJ
interviews  ||| S:320 E:331 ||| NNS
were  ||| S:331 E:336 ||| VBD
performed  ||| S:336 E:346 ||| VBN
with  ||| S:346 E:351 ||| IN
15  ||| S:351 E:354 ||| CD
fibromyalgia  ||| S:354 E:367 ||| CD
patients  ||| S:367 E:376 ||| NNS
in  ||| S:376 E:379 ||| IN
France ||| S:379 E:385 ||| NNP
,  ||| S:385 E:387 ||| ,
Germany  ||| S:387 E:395 ||| NNP
and  ||| S:395 E:399 ||| CC
Spain ||| S:399 E:404 ||| NNP
.  ||| S:404 E:406 ||| .
Using  ||| S:406 E:412 ||| VBG
patients ||| S:412 E:420 ||| NNS
'  ||| S:420 E:422 ||| POS
wording ||| S:422 E:429 ||| NN
,  ||| S:429 E:431 ||| ,
items  ||| S:431 E:437 ||| NNS
were  ||| S:437 E:442 ||| VBD
generated  ||| S:442 E:452 ||| VBN
simultaneously  ||| S:452 E:467 ||| RB
in  ||| S:467 E:470 ||| IN
French ||| S:470 E:476 ||| JJ
,  ||| S:476 E:478 ||| ,
German ||| S:478 E:484 ||| NNP
,  ||| S:484 E:486 ||| ,
Spanish ||| S:486 E:493 ||| NNP
,  ||| S:493 E:495 ||| ,
and  ||| S:495 E:499 ||| CC
UK  ||| S:499 E:502 ||| NNP
English ||| S:502 E:509 ||| NNP
.  ||| S:509 E:511 ||| .
Relevance  ||| S:511 E:521 ||| NNP
and  ||| S:521 E:525 ||| CC
comprehension  ||| S:525 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
the  ||| S:542 E:546 ||| DT
resulting  ||| S:546 E:556 ||| JJ
questionnaire  ||| S:556 E:570 ||| NN
versions  ||| S:570 E:579 ||| NNS
were  ||| S:579 E:584 ||| VBD
tested  ||| S:584 E:591 ||| VBN
with  ||| S:591 E:596 ||| IN
21  ||| S:596 E:599 ||| CD
additional  ||| S:599 E:610 ||| JJ
fibromyalgia  ||| S:610 E:623 ||| JJ
patients ||| S:623 E:631 ||| NNS
;  ||| S:631 E:633 ||| :
questionnaires  ||| S:633 E:648 ||| NNS
were  ||| S:648 E:653 ||| VBD
revised  ||| S:653 E:661 ||| VBN
accordingly ||| S:661 E:672 ||| RB
.  ||| S:672 E:674 ||| .
Three  ||| S:674 E:680 ||| CD
domains ||| S:680 E:687 ||| NN
,  ||| S:687 E:689 ||| ,
Burden  ||| S:689 E:696 ||| RB
associated  ||| S:696 E:707 ||| VBN
with  ||| S:707 E:712 ||| IN
the  ||| S:712 E:716 ||| DT
impacts  ||| S:716 E:724 ||| NN
of  ||| S:724 E:727 ||| IN
fibromyalgia ||| S:727 E:739 ||| NN
,  ||| S:739 E:741 ||| ,
Symptoms  ||| S:741 E:750 ||| NNP
and  ||| S:750 E:754 ||| CC
Influencing  ||| S:754 E:766 ||| NNP
factors ||| S:766 E:773 ||| NNS
,  ||| S:773 E:775 ||| ,
were  ||| S:775 E:780 ||| VBD
identified  ||| S:780 E:791 ||| VBN
from  ||| S:791 E:796 ||| IN
the  ||| S:796 E:800 ||| DT
literature  ||| S:800 E:811 ||| NN
review ||| S:811 E:817 ||| NN
.  ||| S:817 E:819 ||| .
Following  ||| S:819 E:829 ||| VBG
patient  ||| S:829 E:837 ||| JJ
interviews ||| S:837 E:847 ||| NNS
,  ||| S:847 E:849 ||| ,
the  ||| S:849 E:853 ||| DT
burden  ||| S:853 E:860 ||| NN
domain  ||| S:860 E:867 ||| NN
was  ||| S:867 E:871 ||| VBD
further  ||| S:871 E:879 ||| RB
divided  ||| S:879 E:887 ||| VBN
based  ||| S:887 E:893 ||| VBN
on  ||| S:893 E:896 ||| IN
the  ||| S:896 E:900 ||| DT
nature  ||| S:900 E:907 ||| NN
of  ||| S:907 E:910 ||| IN
the  ||| S:910 E:914 ||| DT
impact ||| S:914 E:920 ||| NN
:  ||| S:920 E:922 ||| :
Pain ||| S:922 E:926 ||| NNP
,  ||| S:926 E:928 ||| ,
Physical  ||| S:928 E:937 ||| JJ
impact  ||| S:937 E:944 ||| NN
( ||| S:944 E:945 ||| -LRB-
including  ||| S:945 E:955 ||| VBG
tiredness ||| S:955 E:964 ||| NN
,  ||| S:964 E:966 ||| ,
sleep  ||| S:966 E:972 ||| JJ
problems  ||| S:972 E:981 ||| NNS
and  ||| S:981 E:985 ||| CC
other  ||| S:985 E:991 ||| JJ
symptoms ||| S:991 E:999 ||| NNS
) ||| S:999 E:1000 ||| -RRB-
,  ||| S:1000 E:1002 ||| ,
Activities  ||| S:1002 E:1013 ||| NNP
of  ||| S:1013 E:1016 ||| IN
Daily  ||| S:1016 E:1022 ||| NNP
Living  ||| S:1022 E:1029 ||| NNP
impact  ||| S:1029 E:1036 ||| NN
( ||| S:1036 E:1037 ||| -LRB-
including  ||| S:1037 E:1047 ||| VBG
autonomy  ||| S:1047 E:1056 ||| NN
and  ||| S:1056 E:1060 ||| CC
coping ||| S:1060 E:1066 ||| VBG
) ||| S:1066 E:1067 ||| -RRB-
,  ||| S:1067 E:1069 ||| ,
Social  ||| S:1069 E:1076 ||| NNP
and  ||| S:1076 E:1080 ||| CC
Family  ||| S:1080 E:1087 ||| NNP
Life  ||| S:1087 E:1092 ||| NNP
impact ||| S:1092 E:1098 ||| NN
,  ||| S:1098 E:1100 ||| ,
Work ||| S:1100 E:1104 ||| NNP
,  ||| S:1104 E:1106 ||| ,
Studies  ||| S:1106 E:1114 ||| NNPS
and  ||| S:1114 E:1118 ||| CC
Personal  ||| S:1118 E:1127 ||| NNP
Finances  ||| S:1127 E:1136 ||| NNP
impact ||| S:1136 E:1142 ||| NN
,  ||| S:1142 E:1144 ||| ,
Psychological  ||| S:1144 E:1158 ||| NNP
impact  ||| S:1158 E:1165 ||| NN
( ||| S:1165 E:1166 ||| -LRB-
including  ||| S:1166 E:1176 ||| VBG
cognitive  ||| S:1176 E:1186 ||| JJ
impact ||| S:1186 E:1192 ||| NN
) ||| S:1192 E:1193 ||| -RRB-
,  ||| S:1193 E:1195 ||| ,
and  ||| S:1195 E:1199 ||| CC
Relationship  ||| S:1199 E:1212 ||| NNP
to  ||| S:1212 E:1215 ||| TO
Medicine  ||| S:1215 E:1224 ||| NNP
and  ||| S:1224 E:1228 ||| CC
Disease ||| S:1228 E:1235 ||| NNP
.  ||| S:1235 E:1237 ||| .
The  ||| S:1237 E:1241 ||| DT
resulting  ||| S:1241 E:1251 ||| JJ
test  ||| S:1251 E:1256 ||| NN
versions  ||| S:1256 E:1265 ||| NNS
of  ||| S:1265 E:1268 ||| IN
the  ||| S:1268 E:1272 ||| DT
questionnaire  ||| S:1272 E:1286 ||| NN
contained  ||| S:1286 E:1296 ||| VBD
79  ||| S:1296 E:1299 ||| CD
items ||| S:1299 E:1304 ||| NNS
.  ||| S:1304 E:1306 ||| .
Comprehension  ||| S:1306 E:1320 ||| JJ
tests  ||| S:1320 E:1326 ||| NNS
identified  ||| S:1326 E:1337 ||| VBN
problematic  ||| S:1337 E:1349 ||| JJ
items  ||| S:1349 E:1355 ||| NNS
and  ||| S:1355 E:1359 ||| CC
cultural  ||| S:1359 E:1368 ||| JJ
differences  ||| S:1368 E:1380 ||| NNS
and  ||| S:1380 E:1384 ||| CC
suggested  ||| S:1384 E:1394 ||| VBD
deletions  ||| S:1394 E:1404 ||| NNS
or  ||| S:1404 E:1407 ||| CC
rewording ||| S:1407 E:1416 ||| NN
.  ||| S:1416 E:1418 ||| .
After  ||| S:1418 E:1424 ||| IN
revision  ||| S:1424 E:1433 ||| NN
and  ||| S:1433 E:1437 ||| CC
linguistic  ||| S:1437 E:1448 ||| JJ
harmonization ||| S:1448 E:1461 ||| NN
,  ||| S:1461 E:1463 ||| ,
the  ||| S:1463 E:1467 ||| DT
pilot  ||| S:1467 E:1473 ||| NN
version  ||| S:1473 E:1481 ||| NN
of  ||| S:1481 E:1484 ||| IN
the  ||| S:1484 E:1488 ||| DT
questionnaire  ||| S:1488 E:1502 ||| NN
contained  ||| S:1502 E:1512 ||| VBD
62  ||| S:1512 E:1515 ||| CD
items  ||| S:1515 E:1521 ||| NNS
divided  ||| S:1521 E:1529 ||| VBN
into  ||| S:1529 E:1534 ||| IN
7  ||| S:1534 E:1536 ||| CD
sections ||| S:1536 E:1544 ||| NNS
,  ||| S:1544 E:1546 ||| ,
and  ||| S:1546 E:1550 ||| CC
was  ||| S:1550 E:1554 ||| VBD
named  ||| S:1554 E:1560 ||| VBN
Fibromyalgia  ||| S:1560 E:1573 ||| NNP
Burden  ||| S:1573 E:1580 ||| NNP
Assessment  ||| S:1580 E:1591 ||| NNP
( ||| S:1591 E:1592 ||| -LRB-
FMBAÂ© ||| S:1592 E:1597 ||| NNP
) ||| S:1597 E:1598 ||| -RRB-
.  ||| S:1598 E:1600 ||| .
The  ||| S:1600 E:1604 ||| DT
FMBA  ||| S:1604 E:1609 ||| NNP
is  ||| S:1609 E:1612 ||| VBZ
a  ||| S:1612 E:1614 ||| DT
self-reported  ||| S:1614 E:1628 ||| JJ
questionnaire  ||| S:1628 E:1642 ||| NN
allowing  ||| S:1642 E:1651 ||| VBG
the  ||| S:1651 E:1655 ||| DT
assessment  ||| S:1655 E:1666 ||| NN
and  ||| S:1666 E:1670 ||| CC
a  ||| S:1670 E:1672 ||| DT
better  ||| S:1672 E:1679 ||| JJR
understanding  ||| S:1679 E:1693 ||| NN
of  ||| S:1693 E:1696 ||| IN
the  ||| S:1696 E:1700 ||| DT
impacts  ||| S:1700 E:1708 ||| NN
of  ||| S:1708 E:1711 ||| IN
fibromyalgia  ||| S:1711 E:1724 ||| NN
and  ||| S:1724 E:1728 ||| CC
the  ||| S:1728 E:1732 ||| DT
burden  ||| S:1732 E:1739 ||| NN
associated  ||| S:1739 E:1750 ||| VBN
with  ||| S:1750 E:1755 ||| IN
these  ||| S:1755 E:1761 ||| DT
on  ||| S:1761 E:1764 ||| IN
patients ||| S:1764 E:1772 ||| NNS
'  ||| S:1772 E:1774 ||| POS
daily  ||| S:1774 E:1780 ||| JJ
lives ||| S:1780 E:1785 ||| NNS
.  ||| S:1785 E:1787 ||| .
It  ||| S:1787 E:1790 ||| PRP
is  ||| S:1790 E:1793 ||| VBZ
available  ||| S:1793 E:1803 ||| JJ
in  ||| S:1803 E:1806 ||| IN
UK  ||| S:1806 E:1809 ||| NNP
English ||| S:1809 E:1816 ||| NNP
,  ||| S:1816 E:1818 ||| ,
French ||| S:1818 E:1824 ||| NNP
,  ||| S:1824 E:1826 ||| ,
German  ||| S:1826 E:1833 ||| JJ
and  ||| S:1833 E:1837 ||| CC
Spanish ||| S:1837 E:1844 ||| NNP
.  ||| S:1844 E:1846 ||| .
Its  ||| S:1846 E:1850 ||| PRP$
scoring  ||| S:1850 E:1858 ||| NN
and  ||| S:1858 E:1862 ||| CC
validation  ||| S:1862 E:1873 ||| NNS
remain  ||| S:1873 E:1880 ||| VBP
to  ||| S:1880 E:1883 ||| TO
be  ||| S:1883 E:1886 ||| VB
undertaken ||| S:1886 E:1896 ||| VBN
.  ||| S:1896 E:1898 ||| .
